Johnson & Johnson Fined $1.2 Billion for Concealing Dangers of Drug

On Wednesday, April 11, 2012, an Arkansas court fined healthcare giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, $1.2 billion after a jury found that the companies had minimized or concealed the dangers associated with the drug, Risperdal. The fine was for nearly 240,000 violations of the Arkansas Medicaid fraud law, as well as for violations of the state’s deceptive practices act.
Risperdal is was approved by the FDA to treat schizophrenia, bipolar disorder and behavior problems in autistic children and teens. According to the Arkansas judge, Johnson & Johnson and Janssen concealed or minimized the risks of side effects that an increased risk of diabetes and weight gain, and, in older patients, an increased risk of stroke.
According to an attorney representing a “whistleblower” in a similar Texas case, “[Johnson & Johnson and Janssen] were trumpeting it as a miracle, breakthrough drug,” but it was no better than cheaper generic alternatives. “It was grossly overpriced in relation to its qualities.”
If you or a loved one has been injured as a result of taking Risperdal, contact TERRELL HOGAN to discuss your legal rights.
Drug Giant Is Fined $1.2 Billion in Risperdal Case – NYTimes.com
Chris Shakib is a former prosecutor who represents the victims of dangerous drugs, medical devices, and consumer products.

About The Author

Christopher Shakib

Christopher Shakib

Chris began his career fighting for victims’ rights as a state prosecutor of violent criminals. From 1992 to 1996, he prosecuted bad guys and witnessed the life-long harm criminals inflicted on their victims, because they made a conscious decision to do wrong, often for financial gain.